Tablets & Capsules


Issue link:

Contents of this Issue


Page 7 of 67

6 October 2018 Tablets & Capsules Encapsulated ionic formulation may simplify treatment for diabetes patients CAMBRIDGE, MA—Researchers at Harvard University are develop- ing an oral treatment for type-1 dia- betes that could increase patient compliance and make life easier for patients who would otherwise have to give themselves daily injections. Because the insulin protein breaks down in stomach acid and is poorly absorbed outside of the intestines, researchers used an ionic liquid of choline and geranic acid as a carrier for the insulin and delivered the for- mulation in an acid-resistant, enter- ic-coated capsule that dissolves in the small intestine. The choline and geranic acid allowed insulin mole- cules to pass through the intestine's mucus lining and the tight cell junc- tions of the intestine wall. In addi- tion to being easy to manufacture, biocompatible, and easier to store t h a n i n j e c t a b l e i n s u l i n , o r a l l y ingested insulin would more closely mimic the way a healthy pancreas makes and delivers insulin to the liver. The ionic liquid insulin formu- lation can be prepared in a one-step process that could be easily scaled for commercial production. markets Aging population and other factors to drive growth in global pharmaceutical drug market LYON, France—The global phar- maceutical drug market is expected to grow at a compound annual rate of 5.78 percent and will be worth $1.17 trillion by 2021, according to a report by ReportLinker. Growth factors include aging populations, income growth, and high prices for novel drugs. The US accounted for 25.1 percent of the market in 2017 and will continue to lead the market through the forecast period. US to lead pharmaceutical contract manufacturing market in 2022 LONDON, UK—The pharma- ceutical contract manufacturing cal-stage biotechnology company. In this clinical trial, 66 adult sub- jects were randomly selected to receive the tablet vaccine or a pla- cebo. The results showed that the vaccine was well-tolerated and gen- erated substantial immune responses from the vaccine recipients. The results of this Phase 1 study were published in the Journal of Clinical Investigation Insight. research Tablet vaccine may cure winter vomiting bug S A N F R A N C I S C O , C A — A n oral recombinant vaccine for noro- virus, also known as the winter vomiting bug, may soon be avail- a b l e i n a t a b l e t d o s a g e f o r m , according to the results of a Phase 1 clinical trial by Vaxart, a clini- SANITARY/USDA-ACCEPTED • PNEUMATIC CONVEYING COMPONENTS & SYSTEMS • BATCH & CONTINUOUS OPERATION MULTI-INGREDIENT HANDLING SYSTEMS • BATCH WEIGHING & SCALING SYSTEMS • UL-CONTROLS & CONTROL PACKAGES FDA-APPROVED/CERTIFIED MATERIALS OF CONSTRUCTION • 21 CFR PART 11 COMPLIANCE • GEL CAP CONVEYORS MOBILE VACUUM CONVEYING SYSTEMS • CIP DESIGNS • COMBUSTIBLE DUST INDUSTRIAL VACUUM CLEANERS Let us solve your pneumatic conveying challenges. Visit or call 800-VAC-U-MAX. With more than 60 years of custom application experience in the pharmaceutical industry. Over 10,000 various powder & bulk materials handled. Technical expertise including FAT & SAT validation. And an airtight performance guarantee. It's what makes VAC-U-MAX as unique & trusted as the process automation solutions we design. From sanitary components to fully automated systems, we create pharmaceutical processing solutions entirely around your needs and goals. VAC-U-MAX MDL105017— Sanitary Vacuum Receiver for fine powders & granules. Booth 8414

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC1018